Deadline Approaching for Elanco Animal Advised by Berger Montague

Investors, listen up! Berger Montague PC has some important news for you. There’s a securities class action lawsuit against Elanco Animal Health Inc. (“Elanco” or the “Company”) (NYSE: ELAN) for folks who bought Elanco securities between November 7, 2023, and June 26, 2024 (the “Class Period”). If you fall into that category, you have until December 6, 2024, to potentially be the lead plaintiff representing the class.

Elanco is a company that focuses on developing products for pets and farm animals, like Zenrelia, a medication for canine dermatology, and Credelio Quattro, a treatment for dogs’ parasitic issues.

Throughout the Class Period, the lawsuit alleges that Elanco wasn’t totally upfront about Zenrelia’s safety and also might not have been able to stick to its promises about FDA approval and launch dates for Zenrelia and Credelio Quattro.

On June 27, 2024, Elanco shared updates on FDA approval timelines for Zenrelia and Credelio Quattro. They mentioned that Zenrelia might require additional safety warnings and that FDA approval and commercial launch dates would likely be pushed back. As a result, Elanco’s stock price fell by 20% on that day.

If you want to know more about the lawsuit or potentially be a lead plaintiff (representing the class), you can contact Berger Montague. They’ve been in the securities class action game since 1970 and have a track record of representing investors like you.

Investing can be complex, and it’s important to stay informed about any developments that could impact your investments. Stay tuned for more updates as this case progresses.